Online inquiry

IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6903MR)

This product GTTS-WQ6903MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Alkaline phosphatase substitute gene. The antibody can be applied in Hypophosphatasia (HPP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000478.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 249
UniProt ID P05186
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6903MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5245MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ13792MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ10944MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ6690MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ388MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ8994MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ8074MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ13455MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW